4-氨基-7-氟喹唑啉 | 1009036-29-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-氨基-7-氟喹唑啉
• 中文别名: 7-氟-4-喹唑啉胺
• 英文名称: 4-amino-7-fluoroquinazoline
• 英文别名: 7-fluoroquinazolin-4-amine；7-fluoro-quinazolin-4-ylamine
• CAS: 1009036-29-6
• 化学式: C₈H₆FN₃
• 分子量: 163.154
• InChiKey: OYFIRSZBPDFONT-UHFFFAOYSA-N

物化性质

• 沸点：
  331.8±27.0 °C(Predicted)
• 密度：
  1.400±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  4-氨基-7-氟喹唑啉 在 肼 作用下， 以 乙醇 为溶剂， 反应 22.0h， 生成 1-(4-Amino-quinazolin-7-yl)-3-cyclopropylmethyl-6,6-dimethyl-1,5,6,7-tetrahydro-indazol-4-one
  参考文献：
  名称：

  Isoquinoline, Quinazoline and Phthalazine Derivatives

  摘要：

  本申请揭示了式I的化合物和药学上可接受的盐，其中R0、R5、R6、R7、n、Q1-Q5、Y和X1-X3如本文所定义。式I的化合物在治疗与细胞增殖相关的疾病和/或状况方面具有用途，如癌症、炎症、关节炎、血管生成等。还揭示了包括本发明的化合物的药物组合物以及使用这些化合物治疗上述疾病的方法。

  公开号：

  US20080070935A1
• 作为产物：
  描述：

  2,4-二氟苯腈 、 甲脒 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-氨基-7-氟喹唑啉
  参考文献：
  名称：

  Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90

  摘要：

  A novel class of Hsp90 inhibitors, structurally distinct from previously reported scaffolds, was developed from rational design and optimization of a compound library screen hit. These aminoquinazoline derivatives, represented by compound 15 (SNX-6833) or 1-(2-amino-4-methylquinazolin-7-yl)-3,6,6-trimethyl-6,7-dihydro-1H-indol-4(5H)-one, selectively bind to Hsp90 and inhibit its cellular activities at concentrations as low as single digit nanomolar. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.137

文献信息

• [EN] AMINOMETHYL QUINOLONE COMPOUNDS<br/>[FR] COMPOSÉS D'AMINOMÉTHYL-QUINOLONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013007676A1

  公开（公告）日：2013-01-17

  The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula (I): wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

  这项发明涉及JNK抑制剂及相应的用于抑制JNK和治疗JNK介导的疾病的方法、配方和组合物。该申请披露了JNK抑制剂，如下所述的化学式(I)：其中变量如本文所定义。本文披露的化合物和组合物可用于调节JNK的活性并治疗与JNK活性相关的疾病。还披露了用于抑制JNK和治疗JNK介导的疾病等的方法和配方，以及用于制备上述化合物和相应组合物的过程。
• [EN] SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS<br/>[FR] DIHYDROIMIDAZOPYRIDINEDIONES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE MKNK1 ET DE MKNK2
  申请人：BAYER PHARMA AG

  公开号：WO2018134148A1

  公开（公告）日：2018-07-26

  The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (A) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（A）所描述和定义的取代二氢咪唑吡啶二酮化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和复合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是治疗过度增殖、血管生成障碍、炎症性疾病或与炎症性疼痛相关的疾病的药物组合物，作为单一药剂或与其他活性成分结合使用。
• [EN] ANTIMICROBIAL COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT OF INFECTIONS<br/>[FR] COMPOSITIONS ANTIMICROBIENNES, LEURS MÉTHODES D'UTILISATION, ET MÉTHODES DE TRAITEMENT D'INFECTIONS
  申请人：UNIV SOUTH FLORIDA

  公开号：WO2016191412A1

  公开（公告）日：2016-12-01

  The present disclosure provides compositions including a compound (e.g., compounds A-D), pharmaceutical compositions including the compound, methods of treatment of a condition (e.g., an infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.

  本公开提供包括化合物（例如，化合物A-D）的组合物、包括该化合物的药物组合物、治疗疾病或疾病的方法、使用组合物或药物组合物的治疗方法等。
• AMINOMETHYL QUINOLONE COMPOUNDS
  申请人：Bilotta Joseph A.

  公开号：US20130018043A1

  公开（公告）日：2013-01-17

  The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

  本发明涉及JNK抑制剂及其相应的方法、配方和组合物，用于抑制JNK并治疗JNK介导的疾病。本申请公开了JNK抑制剂，如下式I所述：其中变量如本文所定义。本文所披露的化合物和组合物，有利于调节JNK的活性并治疗与JNK活性相关的疾病。本文披露了用所述化合物抑制JNK和治疗JNK介导的疾病的方法和配方，以及制备上述化合物和相应组合物的过程。
• Aminomethyl quinolone compounds
  申请人：Bilotta Joseph A.

  公开号：US08501732B2

  公开（公告）日：2013-08-06

  The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

  该发明涉及JNK抑制剂及相应的方法、配方和组成物，用于抑制JNK并治疗JNK介导的疾病。该申请披露了如下式I所述的JNK抑制剂：其中变量如本文所定义。本文所披露的化合物和组成物有用于调节JNK活性并治疗与JNK活性相关的疾病。本文还披露了使用上述化合物的方法和配方，用于抑制JNK并治疗JNK介导的疾病等，以及制备上述化合物和相应组成物的过程。